Ro Unveils Eight New Studies at ObesityWeek 2026

New research explores real-world GLP-1 outcomes, food noise, and access to care, highlighting the potential to accelerate discovery and improve patient care

November 14, 2026 - Ro today announced eight studies being presented at ObesityWeek 2026, including research examining early use of oral GLP-1s, food noise, cancer history, and insurance barriers. Every day, thousands of patients start on Ro, and this research demonstrates how real-world patient experiences can generate insights to improve care and advance obesity medicine.

"GLP-1 medications are changing what's possible in obesity medicine, but there's still so much to learn about how patients experience them in everyday life," said Dr. Melynda Barnes, Chief Medical Officer of Ro. "We want to understand how people feel during treatment, how their relationship with food changes, and what gets in the way of accessing care in the first place. By studying real patient experiences at scale, we can uncover insights that help us make care better for the next person on Ro and beyond."

Ro's research explores some of the most important questions in obesity care today, including:

• Who's taking oral GLP-1s, and what are their experiences? Three studies examine patients starting treatment with an oral GLP-1, including who is seeking treatment, early weight loss outcomes, and reported side effects.

• How does GLP-1 treatment affect food noise? Two studies use the validated Ro Allison Indiana Dhurandhar Food Noise (RAID-FN) Inventory to measure changes in food noise among patients taking either oral or injectable GLP-1s.

• How does obesity treatment fit in patients' broader health journeys? Two studies evaluate weight loss outcomes among patients with severe obesity and self-reported cancer history among patients seeking GLP-1 treatment.

• How does insurance coverage restrict treatment access? Research examines the gap between patients who clinically qualify for GLP-1 treatment and those who can obtain insurance coverage for it, revealing barriers that can stand between patients and their prescribed care.

The research was conducted by Ro's scientific affairs team, working alongside Ro's clinical advisors, Drs. Beverly Tchang and Louis Aronne and collaborators from the American Cancer Society, Amgen, and Novo.

This research is powered by Ro Research Lab, the company's new initiative using structured data, AI, and rigorous science to fuel discovery and turn evidence into better clinical guidance, tools, and care for patients.

Findings will be presented at ObesityWeek 2026, November 14-17. Visit here for more information and check out each of the posters here.